LeMaitre Vascular - 500 Beiträge pro Seite
eröffnet am 22.02.17 12:22:21 von
neuester Beitrag 21.02.19 09:10:12 von
neuester Beitrag 21.02.19 09:10:12 von
Beiträge: 4
ID: 1.247.347
ID: 1.247.347
Aufrufe heute: 0
Gesamt: 327
Gesamt: 327
Aktive User: 0
ISIN: US5255582018 · WKN: A0LB2B
59,00
EUR
0,00 %
0,00 EUR
Letzter Kurs 12:31:20 Lang & Schwarz
Neuigkeiten
19.04.24 · globenewswire  |
26.03.24 · globenewswire |
01.03.24 · globenewswire |
27.02.24 · globenewswire |
13.02.24 · globenewswire |
Werte aus der Branche Gesundheitswesen
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 3,2100 | +24,90 | |
| 0,5501 | +18,33 | |
| 0,6080 | +18,06 | |
| 0,6300 | +14,55 | |
| 1,6003 | +14,31 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,5925 | -15,36 | |
| 1,5500 | -19,27 | |
| 2,7600 | -20,69 | |
| 0,9102 | -42,03 | |
| 0,7500 | -48,98 |
Feedback
Q4 2016 Record Sales $23.3 mm (+14%), Op. Income $3.9 mm (+27%)
BURLINGTON, Mass., Feb. 21, 2017 (GLOBE NEWSWIRE) --
LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q4 2016 results, provided guidance, and announced a 22% dividend increase to $0.055/share.
Q4 2016 Results
Record sales of $23.3mm, +14% vs. Q4 2015
Operating income of $3.9mm vs. $3.1mm, +27%
Net income of $2.6mm vs. $2.5mm, +3%
Earnings of $0.13 per diluted share vs. $0.13
EBITDA of $4.8mm vs. $4.0mm, +18%
Q4 2016 sales of $23.3mm increased 14% (+11% organic) vs. Q4 2015. XenoSure and AnastoClip led growth. Sales in the Americas were up 17% while international sales increased 9%.
Gross margin decreased to 69.5% in Q4 2016 from 70.3% in Q4 2015 primarily due to product and geographic mix.
Operating expenses in Q4 2016 were $12.3mm, a 9% increase vs. the year-earlier quarter. The Company ended the quarter with 96 sales reps vs. 86 at the end of Q4 2015.
Full Year 2016 Results
Sales of $89.2mm, +14% reported (+12% organic) vs. 2015
Operating income of $16.3mm vs. $11.5mm, +42%
Net income of $10.6mm vs. $7.8mm, +37%
EPS of $0.55 per diluted share vs. $0.42, +30%
Dividends paid of $0.18 per share vs $0.16, +13%
EBITDA of $19.8mm vs. $14.8mm, +34%
George W. LeMaitre, Chairman and CEO said, “Sales increased 14% in 2016, while operating income was up 42%. We continue to pursue 10% annual reported sales growth and 20% annual operating income growth.”
BURLINGTON, Mass., Feb. 21, 2017 (GLOBE NEWSWIRE) --
LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q4 2016 results, provided guidance, and announced a 22% dividend increase to $0.055/share.
Q4 2016 Results
Record sales of $23.3mm, +14% vs. Q4 2015
Operating income of $3.9mm vs. $3.1mm, +27%
Net income of $2.6mm vs. $2.5mm, +3%
Earnings of $0.13 per diluted share vs. $0.13
EBITDA of $4.8mm vs. $4.0mm, +18%
Q4 2016 sales of $23.3mm increased 14% (+11% organic) vs. Q4 2015. XenoSure and AnastoClip led growth. Sales in the Americas were up 17% while international sales increased 9%.
Gross margin decreased to 69.5% in Q4 2016 from 70.3% in Q4 2015 primarily due to product and geographic mix.
Operating expenses in Q4 2016 were $12.3mm, a 9% increase vs. the year-earlier quarter. The Company ended the quarter with 96 sales reps vs. 86 at the end of Q4 2015.
Full Year 2016 Results
Sales of $89.2mm, +14% reported (+12% organic) vs. 2015
Operating income of $16.3mm vs. $11.5mm, +42%
Net income of $10.6mm vs. $7.8mm, +37%
EPS of $0.55 per diluted share vs. $0.42, +30%
Dividends paid of $0.18 per share vs $0.16, +13%
EBITDA of $19.8mm vs. $14.8mm, +34%
George W. LeMaitre, Chairman and CEO said, “Sales increased 14% in 2016, while operating income was up 42%. We continue to pursue 10% annual reported sales growth and 20% annual operating income growth.”
Antwort auf Beitrag Nr.: 54.381.892 von R-BgO am 22.02.17 12:22:21
sehr gute Zahlen für 2017,
verteuernd aufgestockt 
Antwort auf Beitrag Nr.: 58.894.380 von R-BgO am 08.10.18 13:41:56
geht auch in die andere Richtung:
+22% gestern nach den Q4-Zahlen 
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| -3,40 | |
| +0,13 | |
| -0,10 | |
| +1,81 | |
| +3,85 | |
| +0,72 | |
| -0,48 | |
| -0,14 | |
| +3,88 | |
| -0,57 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 185 | ||
| 126 | ||
| 90 | ||
| 66 | ||
| 65 | ||
| 50 | ||
| 41 | ||
| 32 | ||
| 32 | ||
| 31 |
